Cargando…

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors

Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insuli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pruett, Jacob E., Romero, Damian G., Yanes Cardozo, Licy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974663/ https://www.ncbi.nlm.nih.gov/pubmed/36875461 http://dx.doi.org/10.3389/fendo.2023.951099

Ejemplares similares

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

SAT381 Effect of Obesity on Androgen-induced Splenic Dysregulation in Polycystic Ovary Syndrome
por: Rezq, Samar, et al.
Publicado: (2023)

Androgen Receptor Blocker Improves the Cardiometabolic Profile in a Rat Model of Polycystic Ovary Syndrome, but at What Cost?
por: Pruett, Jacob E, et al.
Publicado: (2021)

Hepatic Dysregulation of Bile Acid Homeostasis in Hyperandrogenemic Female Mouse Model of Polycystic Ovary Syndrome
por: Huffman, Alexandra M, et al.
Publicado: (2021)

Long-Lasting Androgen-Induced Cardiometabolic Effects in Polycystic Ovary Syndrome
por: Torres Fernandez, Edgar D, et al.
Publicado: (2018)

Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome
por: Pruett, Jacob E., et al.
Publicado: (2021)

OR15-3 Contribution of Hyperandrogenemia to Dysbiosis, Gut Inflammation, and Dysregulation of Short-Chain Fatty Acid Homeostasis in Mouse Model of Polycystic Ovary Syndrome
por: Alsemeh, Amira, et al.
Publicado: (2022)

RF10 | PMON249 MicroRNA-21 Ablation Exacerbates Androgen-Mediated White Adipose Tissue Dysfunction and Impaired Insulin Signaling in a Mouse Model of Polycystic Ovary Syndrome
por: Rezq, Samar, et al.
Publicado: (2022)

OR35-02 Novel Androgen Receptor PROTAC Degrader ARV-110 Ameliorates Androgen Mediated Renal Injury in a Mouse Model of Polycystic Ovary Syndrome
por: Basnet, Jelina, et al.
Publicado: (2023)

A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
por: Sinha, Binayak, et al.
Publicado: (2022)

MicroRNA-21 Modulates White Adipose Tissue Browning and Altered Thermogenesis in a Mouse Model of Polycystic Ovary Syndrome
por: Rezq, Samar, et al.
Publicado: (2021)

Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol
por: Zhang, Jiaqi, et al.
Publicado: (2022)

Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19
por: Rezq, Samar, et al.
Publicado: (2021)

Novel biomarkers of childhood and adolescent obesity
por: Yanes Cardozo, Licy L., et al.
Publicado: (2021)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

Clinical Practice Guideline for Management of Primary Aldosteronism: What is New in the 2016 Update?
por: Romero, Damian G, et al.
Publicado: (2016)

Obesity and Outcome of Assisted Reproduction in Patients With Polycystic Ovary Syndrome
por: Tziomalos, Konstantinos, et al.
Publicado: (2018)

Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
por: Lai, Shih-Wei, et al.
Publicado: (2023)

OR35-01 Colonic Mitochondrial Dysfunction and Sub-acute Gastrointestinal Inflammation in Two Hyperandrogenemic Rodent Models of PCOS
por: Hoang, Ngoc, et al.
Publicado: (2023)

A Low-Carbohydrate Diet Improves Glucose Metabolism in Lean Insulinopenic Akita Mice Along With Sodium-Glucose Cotransporter 2 Inhibitor
por: Fujita, Yukihiro, et al.
Publicado: (2020)

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
por: Afsar, Baris, et al.
Publicado: (2022)

Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
por: Al-Shamasi, Al-Anood, et al.
Publicado: (2021)

Kisspeptin and Polycystic Ovary Syndrome
por: Tang, Rong, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2022)

Influence and mechanism of sodium-glucose cotransporter-2 inhibitors on the cardiac function: study protocol for a prospective cohort study
por: Cao, Min-Jia, et al.
Publicado: (2023)

Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome
por: Zhou, Ling, et al.
Publicado: (2020)

Telomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome
por: Velazquez, Mariela Edith, et al.
Publicado: (2021)

The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity
por: Abdulkhalikova, D., et al.
Publicado: (2022)

Different sleep pattern in over-weight/obese women with polycystic ovary syndrome
por: Oberg, Emma, et al.
Publicado: (2023)

Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis
por: Wei, Wen, et al.
Publicado: (2022)

The role of the thyroid in polycystic ovary syndrome
por: Fan, Huanhuan, et al.
Publicado: (2023)

Editorial: Epigenetics of polycystic ovary syndrome
por: Parker, Jim, et al.
Publicado: (2023)

A bibliometric and visual analysis of obesity and polycystic ovary syndrome from 2012 to 2022
por: Luo, Ping, et al.
Publicado: (2022)

Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
por: Wang, Dongxu, et al.
Publicado: (2023)

Effect of hyperlipidemia on the outcome of in vitro fertilization in non-obese patients with polycystic ovary syndrome
por: Yang, Fang, et al.
Publicado: (2023)

Cardiometabolic risk in polycystic ovary syndrome
por: Bajuk Studen, Katica, et al.
Publicado: (2018)

PMON225 Androgen excess in pre-menopausal women due to Granulosa Cell tumor: A case report.
por: Kaval, Roopitha, et al.
Publicado: (2022)

Decreased Endometrial Thickness Is Associated With Higher Risk of Neonatal Complications in Women With Polycystic Ovary Syndrome
por: Huang, Jialyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mt41datpi63hbbckdkedn0i7r1